Investor's Business Daily on MSN

IBD stock of the day: Pet-health firm Idexx Laboratories looks to build on 2025 rally

The majority of Idexx's revenue comes from its Companion Animal Group, a segment that includes diagnostic products for vets.

Is It Too Late To Consider Buying IDEXX Laboratories (IDXX) After A 71% One Year Rally

If you are wondering whether IDEXX Laboratories is still fairly priced after a strong run, this article walks through what the current share price could mean for long term investors. The stock last ...
Barchart on MSN

What to expect from IDEXX Laboratories’ next quarterly earnings report

IDEXX Laboratories, Inc. (IDXX) is a multinational healthcare company specializing in the development, manufacture, and ...

IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February 2, 2026 ...
Seeking Alpha

IDEXX: One Of The Best But Too Expensive To Risk It

IDEXX Laboratories is a global company that provides products and services for primarily companion animals. Revenue has grown at a rate of 10%, driven by improving market conditions and an expansion ...
Morningstar

IDEXX Laboratories to Release 2025 First Quarter Financial Results

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the ...
Morningstar

Idexx Remains Best in Show, in Our View; No Change to Our Fair Value Estimate

Idexx Laboratories has steadily increased its scale and reach in the veterinary diagnostic lab business to dig a narrow moat. It is well-positioned to benefit from two key trends. First, pet ownership ...